Olmesartamedoxomil/Hydrochloorthiazide Sandoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartamedoxomil/Hydrochloorthiazide Sandoz, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adults. GNH USA supplies Olmesartamedoxomil/Hydrochloorthiazide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartamedoxomil/Hydrochloorthiazide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/hydrochlorothiazide is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

- Hypertension: helps lower systolic and diastolic blood pressure when used alone or with other antihypertensives. - Heart failure prevention: contributes to reduced risk of cardiovascular events in patients with hypertension. - Chronic kidney disease: assists  as  part of  blood‑pressure control  in  patients  with  early  renal  impairment.

Common Side Effects: - Dizziness  :  light‑headed  feeling  often  transient. - Headache  :  mild  to  moderate  head  pain. - Fatigue  :  generalized  tiredness. - Increased urination  :  more frequent  urine  output. - Electrolyte imbalance  :  changes  in  potassium  or  sodium  levels.

Serious or Rare Side Effects: - Severe hypotension  :  dangerously low blood pressure. - Acute kidney injury  :  rapid  decline  in  renal  function. - Hyperkalemia  :  elevated  potassium  levels. - Angio‑Ang   :  swelling  of  face  or  airway  that  could  threaten  life  if  untreated  . - Liver dysfunction  :  abnormal  liver  enzyme  tests  or  jaundice.

Patients should be evaluated for renal function, electrolyte status, and cardiovascular health before initiating therapy.

- Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: check creatinine and eGFR periodically. - Check electrolytes: especially potassium and sodium levels. - Review concomitant medications: avoid drugs that may cause additive hypotension. - Pregnancy: contraindicated in the second and third trimesters; discuss risks with a physician. - Store at ambient temperature: keep in original packaging, protect from moisture and direct light.

Olmesartan medoxil/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: concurrent use with ACE inhibitors or other ARBs increases risk of kidney injury and hyperkalemia. - Potassium‑rich supplements: may cause dangerous hyper‑kalemia. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Loop diuretics: additive diuretic effect may cause volume depletion. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.